Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 24 December 2025 - 1 January 2026

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

NEW YORK, January 1, 2026, 03:10 ET — Market closed Intelligent Bio Solutions Inc said late Wednesday it will raise about $10 million in a private placement, sending its shares lower in after-hours trading after a sharp rally earlier in the session. The financing lands as the micro-cap medtech company pitches a faster path to scale for its fingerprint-based drug screening reader, with management pointing to lower production costs and higher profitability ahead of a planned U.S. market entry. Private placements are a common funding route for small companies, but they can dilute existing shareholders — meaning each share represents
1 January 2026
··
BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

NEW YORK, December 31, 2025, 15:27 ET — Regular session. Shares of BillionToOne (BLLN.O) fell about 4% on Wednesday, sliding $3.49 to $81.61 in afternoon trading. The stock has traded between $81.25 and $89.36, with about 243,000 shares changing hands. The move came on the final trading day of 2025, when liquidity is typically thin and price swings can look bigger than the underlying news. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking when liquidity is low. U.S. markets are closed on Thursday for New
31 December 2025
··
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

NEW YORK, December 31, 2025, 14:52 ET — Regular session Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500 tracker and Nasdaq 100 fund were both down about 0.4% to 0.5%. The move matters because Cytokinetics is nearing its first U.S. commercial launch after winning FDA approval for Myqorzo (aficamten) this month. The company has said the drug should be available in the U.S. in the second half of January and will be distributed under a REMS program —
31 December 2025
··
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

NEW YORK, December 31, 2025, 14:41 ET — Regular session Axsome Therapeutics shares jumped 23% in afternoon trading on Wednesday after the company said U.S. regulators accepted its application and granted a faster review for AXS-05 to treat agitation in Alzheimer’s disease. GlobeNewswire The FDA’s acceptance puts a hard deadline on the next major catalyst for Axsome, with an April 30, 2026 decision target that brings clarity to the company’s regulatory timeline. The stock move also stood out against the broader biotech group, which was modestly higher. GlobeNewswire Axsome said the FDA granted “Priority Review,” meaning the agency’s goal is
31 December 2025
···
INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

NEW YORK, December 31, 2025, 13:04 ET — Regular session Intelligent Bio Solutions Inc shares surged on Wednesday after the company said it struck a new manufacturing partnership aimed at lowering costs for its fingerprint-based drug testing device. The stock was up $6.56, or about 160%, at $10.66 by 1:04 p.m. ET. Google The announcement matters now because Intelligent Bio is trying to improve its unit economics as it scales. The company said the partnership should drive annual production cost savings of more than 40%, translating to an expected improvement of about 20 percentage points in gross margin. Gross margin
31 December 2025
··
Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

NEW YORK, December 31, 2025, 11:55 ET — Regular session Shares of Cogent Biosciences slid on Wednesday, paring losses from earlier in the session, after the biotech disclosed a key regulatory filing while investors digested a cluster of insider stock sales. The stock was down 2.5% at $36.19, after touching a low of $34.33. The move comes as Cogent shifts from late-stage data to the U.S. Food and Drug Administration review process — a step that can widen the audience beyond biotech specialists and pull more short-term traders into the name. A New Drug Application, or NDA, is the formal
31 December 2025
··
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

NEW YORK, December 30, 2025, 15:32 ET — Regular session GRAIL Inc shares were down 3.3% at $84.95 in afternoon trading on Tuesday, after earlier touching $84.77. The early-cancer detection company is trying to turn Galleri — a multi-cancer early detection (MCED) blood test that screens for signals across many cancers from a single draw — into a mainstream part of care. In its most recent quarterly update, Grail said U.S. Galleri revenue rose 28% year-on-year to $32.6 million and test volumes increased 39%, while it anticipated completing a U.S. premarket approval filing in the first quarter of 2026. GRAIL
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

NEW YORK, December 30, 2025, 14:30 ET — Regular session Shares of Kymera Therapeutics fell about 3% to $77.94 in afternoon trading on Tuesday, lagging a broader biotech dip. The SPDR S&P Biotech ETF was down about 1.4%, while the iShares Nasdaq Biotechnology ETF slipped about 1.1%. The pullback matters because Kymera has been one of the sector’s higher-volatility names this month, after a surge tied to new clinical data and a subsequent stock sale that increased its share count. With most of its next major readouts still far off, investors have been quick to reprice the stock around financing
30 December 2025
··
Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

NEW YORK, December 30, 2025, 05:26 ET — Premarket Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235 shares, above recent daily levels for the thinly traded biotech. StockAnalysis The move matters because Belite is trying to turn a rare-disease eye drug into a first-in-class launch, and the stock is now trading well above the $154 level at which it last sold new shares in a major December offering. In markets where liquidity thins out near year-end, sharp
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

NEW YORK, December 30, 2025, 05:21 ET — Premarket Praxis Precision Medicines Inc shares rose 13.25% on Monday to close at $304.58, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its essential tremor candidate ulixacaltamide, a filing showed. The stock opened at $317.72 and traded between $298 and $317.72, and was down about 1% in after-hours trading. StockAnalysis+2SEC+2 Breakthrough Therapy Designation is an FDA pathway meant to speed development and review for drugs aimed at serious conditions when early clinical evidence suggests a meaningful step up over available therapies. For traders, it often serves as a
30 December 2025
···
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

NEW YORK, December 30, 2025, 01:49 ET — Market closed SELLAS Life Sciences Group Inc (SLS) shares jumped 16.7% on Monday to close at $3.35 after the company updated investors on the timing of a late-stage acute myeloid leukemia (AML) trial. The stock traded between $2.60 and $3.44 and logged about 22.4 million shares, according to StockAnalysis data. StockAnalysis The update matters because REGAL is the company’s main near-term catalyst, and the market is trying to pin down when the final dataset will be ready. In biotech, a change in timing can move shares even when there is no new
30 December 2025
··
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

NEW YORK, December 30, 2025, 00:52 ET — Market closed. Praxis Precision Medicines shares climbed about 13% in Monday’s session, last trading at $304.58, after the company said U.S. regulators granted Breakthrough Therapy Designation for its experimental essential tremor treatment. The stock swung between $318.08 and $275.00 during the day. The designation, known as BTD, is an FDA pathway meant to speed development and review of drugs for serious conditions when early clinical evidence suggests a meaningful improvement over available options. U.S. Food and Drug Administration Praxis said the BTD was granted for ulixacaltamide and that it expects to submit
30 December 2025
··
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead rare-disease program. The stock traded between $0.20 and $0.30, with about 241 million shares changing hands, according to the company’s share data. Mereo BioPharma The miss lands at a delicate moment for the London-based biotech, which has leaned on setrusumab as its most visible late-stage value driver. Investors are now weighing how quickly the company can rein in spending and
30 December 2025
··
Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx stock sinks 42% after Phase 3 setrusumab miss; what RARE investors watch nextNEW YORK, December 29, 2025, 23:21 ET — Market closed

Ultragenyx Pharmaceutical Inc shares slid on Monday after the company said two late-stage studies of setrusumab for osteogenesis imperfecta missed their primary fracture-reduction goal, prompting plans for significant expense reductions. “We are surprised and disappointed by these results,” Chief Executive Emil Kakkis said. Shares last traded down 42.3% at $19.72 after the close, versus a prior close of $34.19, after swinging between $34.50 and $17.76 on volume of about 21.7 million shares. Stock Titan The miss dents a key growth bet for Ultragenyx in a rare genetic bone disorder often called brittle-bone disease. Late-stage trial outcomes can quickly reshape expectations
30 December 2025
·
Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 3:41 a.m. ET — Market closed (weekend). Regencell Bioscience Holdings Limited (NASDAQ: RGC) heads into the weekend with traders focused on one thing: volatility. RGC stock finished the last regular session (Friday) sharply lower, while the broader market logged weekly gains in a quiet, holiday-shortened week—setting up a potentially jumpy start to the next session when U.S. equities reopen on Monday, Dec. 29. Investopedia RGC stock price today: where Regencell Bioscience stands after Friday’s slide RGC shares closed Friday at $21.16, down $3.44 (-13.98%) on the day. Trading was wide, with an intraday range of
28 December 2025
···
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

NEW YORK, Dec. 27, 2025, 8:12 p.m. ET — Market closed Moderna, Inc. (NASDAQ: MRNA) stock heads into the weekend with investors parsing a mix of technical read-throughs, biotech-sector screens, and diverging Wall Street targets after a sharp pullback in the final stretch of the holiday week. Shares of Moderna ended Friday’s regular session at $31.20, down 4.73% on the day, with the stock trading between $31.07 and $32.66. Extended-hours quotes Friday evening were modestly lower, with after-hours trading around $31.1 before markets went dark for the weekend. StockAnalysis+2Investing.com+2 With U.S. equity markets closed Saturday and Sunday, the next actionable
28 December 2025
··
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

NEW YORK, Dec. 27, 2025, 4:58 p.m. ET — Market closed (U.S. equities are shut for the weekend) CRISPR Therapeutics AG (NASDAQ: CRSP) heads into the final trading stretch of 2025 with investors balancing two forces that often define biotech stocks: headline-driven momentum and long-duration fundamental risk. The stock finished the most recent regular session (Friday, Dec. 26) at $55.08, down 2.87%, after trading between $56.54 and $53.76. In after-hours trading, CRSP was last shown around $55.24 late Friday evening. StockAnalysis That Friday move came against a holiday-thinned tape on Wall Street. Reuters described the broader market session as light-volume
27 December 2025
··
Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

New York — Friday, December 26, 2025, 9:08 a.m. ET. U.S. equities are not yet in the regular session as of this writing; the Nasdaq opens at 9:30 a.m. ET. Barron’s That timing matters today because Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is entering the session with multiple company-specific catalysts on the board—most notably China’s approval of COBENFY for schizophrenia, plus updates tied to China’s National Reimbursement Drug List (NRDL) and progress in a key oncology program (zocilurtatug pelitecan, “zoci”). Business Wire Meanwhile, the broader market backdrop is very “holiday week”: thin liquidity, a post‑Christmas reset, and investors still
26 December 2025
···
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. stock exchanges have not yet opened for the regular session (standard hours are 9:30 a.m. to 4:00 p.m. ET). Nasdaq Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is in focus heading into the post-holiday session after the company delivered an encouraging clinical update for EDG-7500—its investigational therapy for hypertrophic cardiomyopathy (HCM)—that helped drive a sharp rally in the last session before Christmas. PR Newswire Where EWTX stock stands pre-market Market data tracked by MarketBeat shows EWTX closing at $27.38 on December 24 (the last regular session before Christmas
26 December 2025
···
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly and Company (NYSE: LLY) wrapped up a holiday-shortened Christmas Eve session with a modest gain — and then drifted slightly lower in thin after-hours trading as investors digested a policy-heavy news cycle around GLP‑1 obesity medicines. With U.S. markets closed on Christmas Day (Thursday, Dec. 25, 2025) and set to reopen Friday (Dec. 26, 2025), today’s late tape is less about big price swings and more about positioning: where Lilly stands in the global obesity market, what Washington’s latest coverage model could mean for pricing and volume, and what catalysts are coming next. AP News Eli Lilly stock
24 December 2025
···
1 … 4 5 6 7 8 … 15

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Go toTop